胞性線維症に対する併用療法
Jeffrey L Brodsky1, Raymond A Frizzell2
1Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Cell
|September 26, 2015
まとめ
cystic fibrosis transmembrane conductance regulator (CFTR) タンパク質の特定の変異によって引き起こされる一般的な遺伝疾患です. 新しい治療法では 補正剤と増強剤を組み合わせて CFTR タンパク質の機能を改善します
科学分野:
- 生物化学
- 遺伝学
- 薬理学について
背景:
- 胞性線維症は一般的な遺伝疾患です.
- 最も一般的な形態は,システィック線維症の膜伝導性調節体 (CFTR) タンパク質におけるアミノ酸の欠失によるものです.
研究 の 目的:
- 最近承認されたCFの治療法を説明します.
- この二重療法アプローチの作用メカニズムを説明します.
主な方法:
- この研究は組み合わせ治療に焦点を当てています.
- この治療には化学補正剤と 強化薬が含まれます
主要な成果:
- CFTRタンパク質の適切な折り畳みを促進する.
- 補強剤は,修正されたCFTRチャネルの活動を強化します.
- この二重行動はCFTR機能を回復することを目的としています.
結論:
- 承認された治療法は 共通の変異を持つ CF患者のための新しい治療戦略を提供します.
- 併用療法では,CFTRタンパク質の折りたたみとチャネル活性の両方に対応します.
- このアプローチはCF治療の 重要な進歩です
関連する概念動画
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combined Effects of Drugs: Synergism
7.5K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
7.5K
Cystic Fibrosis: Pathogenesis
1.1K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.1K
Cystic Fibrosis: Management
620
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
620
Drugs for Treatment of Constipation-Predominant IBS
1.3K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.3K
Pulmonary Tuberculosis V
870
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
870


